source
- Summit Therapeutics' Akeso cuts death risk by 34% in Chinese lung cancer trial presented at ASCO 2026Summit Therapeutics reported at the ASCO 2026 meeting that its experimental drug Akeso lowered the risk of death by 34% for previously untreated lung cancer patients in China when compared with the…
- Ivonescimab cuts death risk by 34% in Chinese trial for squamous NSCLCData presented at the American Society of Clinical Oncology showed that ivonescimab, a bispecific antibody combining two established cancer drugs, lowered the risk of death by 34% compared with sta…